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Abstract
Background: Clinical trials suggest that cyclo-oxygenase-2 specific inhibitors (coxibs) are an
effective treatment for acute postoperative pain. The aims of this systematic review were to
examine the evidence for oral valdecoxib and injected parecoxib, and quantify efficacy and adverse
effects.
Methods: Information from randomized, double-blind studies in acute postoperative pain was
sought. The area under the pain relief versus time curve over four to six hours was dichotomized
using validated equations to derive the proportion of patients with treatment and placebo with at
least 50% pain relief over four to six hours and calculate the number-needed-to-treat (NNT).
Information on duration of analgesia and adverse events was also collected.
Results: The NNT for one patient to experience at least 50% relief over six hours following a
single oral dose of valdecoxib 20 mg and 40 mg was 1.7 (1.4 to 2.0) and 1.6 (1.4 to 1.8) respectively.
The NNT for one patient to have at least 50% relief over four to six hours with parecoxib 20 mg
IV and 40 mg IV was 3.0 (2.3 to 4.1) and 2.3 (2.0 to 2.6) respectively. Mean time to remedication
(weighted by trial size) was >24 hours with valdecoxib 40 mg, 8.7 hours with parecoxib 40 mg IV
and 1.7 to 1.8 hours with placebo. There were no statistical differences between treatment and
placebo for any adverse effect.
Conclusion: Both oral valdecoxib and injected parecoxib are effective treatments for acute
postoperative pain.
Background
Several new cyclo-oxygenase-2 specific inhibitors have
been tested in acute pain. Known as 'coxibs', these drugs
specifically inhibit only one of the two cyclo-oxygenase
isoforms inhibited by older NSAIDs [1,2]. and are
thought to provide comparative efficacy but fewer gas-
trointestinal adverse events in chronic dosing [3,4]. A sys-
tematic review of rofecoxib demonstrated that a 50 mg
dose was effective in treating acute postoperative pain [5].
Not only did rofecoxib 50 mg show four to six hour effi-
cacy at least equivalent to ibuprofen 400 mg and
diclofenac 50 mg, but also a much longer duration as
measured by time to next analgesia. This duration of anal-
gesia was seen primarily in the context of third molar
extractions, and, of course, reflects the high single dose of
rofecoxib in acute pain of 50 mg – twice to four times the
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daily chronic pain dose, reflecting an increased safety of
coxibs over older NSAIDs. Other coxibs have yet to be
evaluated in this way for acute pain.
Valdecoxib is an orally administered coxib [6]. Parecoxib
is the sulphonamide-based pro-drug of valdecoxib and,
for the moment, the only parenterally administered coxib
available [7,8]. There is no evidence that injected NSAIDs
provide any greater degree of pain relief than the same
drugs administered orally [9]. Parenteral preparations
may, however, be particularly useful in the immediate
postoperative period when patients are unable to take oral
medication or are nauseated and vomiting.
Random chance poses a threat to the accuracy and preci-
sion of efficacy estimates from individual trial reports.
Although single clinical trials can demonstrate statistical
superiority of analgesic over placebo, random variation
means that, if small, they provide a poor estimate of effect
size [10]. Combining results from appropriate trials in a
meta-analysis means that more patients are included, giv-
ing a more accurate and reliable estimate of the extent of
analgesia [10,11].
Individual trials in acute dental, gynaecologic and ortho-
paedic pain suggest that valdecoxib and parecoxib are
both efficacious and well tolerated. The aims of this sys-
tematic review were to combine appropriate data to quan-
tify the efficacy, duration of analgesia and associated
adverse effects for single dose valdecoxib and parecoxib in
the treatment of acute postoperative pain.
Methods
QUORUM guidelines were followed [12]. Possible studies
for inclusion were sought through searching PubMed
(Dec 2002) and the Cochrane Library (2002 issue 4) using
parecoxib and valdecoxib as free text terms. Pfizer and
Pharmacia were asked to provide copies of relevant
abstracts and posters. Reference lists and review articles
were examined for possible additional references, and in-
house databases also checked for papers.
Abstracts were examined for possible inclusion if they
were randomized trials conducted in an acute pain setting
and used valdecoxib or parecoxib and a matched placebo
(with or without an active comparator). Criteria for inclu-
sion were: randomized controlled trials which included
single dose treatment groups of valdecoxib or parecoxib,
double blind design, baseline postoperative pain of mod-
erate to severe intensity, patients over 15 years of age, at
least 10 patients per group, and the pain outcome meas-
ures of total pain relief (TOTPAR) or summed pain inten-
sity difference (SPID) over 4–6 hours or sufficient data
provided to allow their calculation. Posters and abstracts
were accepted provided all criteria could be met. Pain
measures allowed for the calculation of TOTPAR or SPID
were a standard five point pain relief scale (none, slight,
moderate, good, complete), a standard four point pain
intensity scale (none, mild, moderate, severe) or a stand-
ard visual analogue scale (VAS) for pain relief or pain
intensity. The dichotomous information from the
number of patients reporting 'good' and 'excellent' on a
standard global scale (poor, fair, good, very good, excel-
lent) were also accepted [13]. Also of interest was infor-
mation on the time to remedication. For adverse events,
the primary outcome sought was the proportion of
patients experiencing any adverse event, with secondary
outcomes of patients experiencing particular adverse
events.
Each report which could possibly be described as a rand-
omized controlled trial was read independently by at least
two authors and scored using a commonly-used three
item, 1–5 score, quality scale [14]. Consensus was then
achieved. The maximum score of an included study was 5
and the minimum score was 2. Authors were not blinded
because they already knew the literature.
For each trial, mean TOTPAR, SPID, VASTOTPAR or
VASSPID values for the first dose from each drug group
were converted to %maxTOTPAR by division into the cal-
culated maximum value [15]. The proportion of patients
in each treatment group who achieved at least 50%max-
TOTPAR was calculated using valid equations [16–18].
The number of patients with at least 50%maxTOTPAR was
then used to calculate relative benefit and NNT for treat-
ment versus placebo. The same methods were used for
adverse events.
Relative benefit and relative risk estimates were calculated
with 95% confidence intervals using a fixed effects model
[19]. Heterogeneity tests were not used as they have previ-
ously been shown to be unhelpful [20,21] though homo-
geneity was examined visually [22]. Publication bias was
not assessed using funnel plots as these tests have been
shown to be unhelpful [23,24]. The number needed to
treat or harm (NNT and NNH) with confidence intervals
was calculated by the method of Cook and Sackett [25]
from the sum of all events and patients for treatment and
placebo.
Relative benefit or risk was considered to be statistically
significant when the 95% confidence interval did not
include 1. NNT or NNH values were only calculated when
the relative risk or benefit was statistically significant, and
are reported with the 95% confidence interval. Statistical
significance of any difference between numbers needed to
treat was assumed if there was no overlap of the confi-
dence intervals and statistically quantified using the z testBMC Anesthesiology 2003, 3 http://www.biomedcentral.com/1471-2253/3/1
Page 3 of 9
(page number not for citation purposes)
[26]. Calculations were performed using Microsoft Excel
2001 on a Power Macintosh G3.
Results
Valdecoxib
Two fully published reports of three trials [27,28] and one
poster [29] were included in the analyses. All four trials
were funded either by Pfizer or Pharmacia, the manufac-
turers of valdecoxib. Details of the design, numbers of
patients, outcomes, analgesic results, adverse events and
quality scores are given in additional file 1. Details of
excluded reports are given in additional file 2. All trials
were in dental pain following third molar extraction.
Including active comparators there were 859 patients
included across the four trials; 101 patients were treated
with valdecoxib 20 mg, 279 with valdecoxib 40 mg and
194 with placebo. Comparator analgesics were rofecoxib
50 mg (183 patients in two trials [27,29].) and oxycodone
10 mg plus paracetamol 1000 mg (102 patients in two tri-
als [28]). Quality scores were 5 for one report (including
two trials), 3 for one report and 2 for one report.
At least 50% pain relief
All three reports provided data that permitted the calcula-
tion of six hour TOTPAR and derivation of the number of
patients with at least 50%maxTOTPAR. Visual assessment
of homogeneity showed all the studies to be in good
agreement and all trials showed statistical benefit of val-
decoxib 20 mg and 40 mg over placebo (Figure 1). Overall
69/101 patients (68%) given valdecoxib 20 mg experi-
enced at least 50% maxTOTPAR over six hours compared
with 8/103 patients (8%) treated with placebo in direct
comparisons. The NNT for one patient to have at least half
pain relief over six hours was 1.7 (1.4 to 2.0). For val-
decoxib 40 mg, 204/279 patients (73%) experienced at
least 50% maxTOTPAR over six hours compared to 19/
194 patients (10%) with placebo in direct comparisons,
the NNT for one patient to have at least half pain relief
over six hours with was 1.6 (1.4 to 1.8) (Table 1).
L'Abbe plot showing trials of valdecoxib 20 mg and 40 mg Figure 1
L'Abbe plot showing trials of valdecoxib 20 mg and 40 mg.
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Remedication time
Median time to remedication was reported in three
reports. The data from one trial [27] did not permit pool-
ing as the design allowed an additional dose of valdecoxib
before patients were classed as having remedicated. For
placebo, the weighted median time to remedication from
153 patients was 1.7 hours. For valdecoxib 20 mg the
weighted median time to remedication based on 101
patients was greater than 17.5 hours. For valdecoxib 40
mg the weighted mean time to remedication based on 199
patients was greater than 24 hours. For oxycodone 10 mg
plus paracetamol 1000 mg the weighted mean time to
remedication was 8.8 hours from 102 patients. For
rofecoxib 50 mg the median time to remedication
reported in one trial [29] was greater than 24 hours.
Adverse effects
No patient was withdrawn as a result of adverse effects.
Adverse effect data for the two trials published in one
report was already pooled [28]. Data from the study with
the unconventional remedication regimen were included.
Pooled analysis of 324 patients comparing valdecoxib 40
mg to placebo did not reveal any statistically significant
differences for 'nausea', 'vomiting', 'dizziness', 'headache'
or 'any event'. The absolute proportions of patients expe-
riencing adverse effects were higher with placebo than
with valdecoxib 40 mg, except for 'vomiting' (Table 2). No
pooled analysis was possible for valdecoxib 20 mg but the
number of patients reporting adverse effects following a
single dose was consistently lower than for placebo.
Parecoxib
Overall, three fully published reports [30–32] and one
poster [33] were included in the analyses. All four trials
were funded by Pharmacia the manufacturers of
parecoxib. Details of the design, numbers of patients, out-
comes, analgesic results, adverse effects and quality scores
are given in additional file 1 (exclusions detailed in addi-
tional file 2). One other poster met the inclusion criteria
but it was not possible to extract relevant data due to poor
print quality and no alternative source of information was
available at the time of writing [34].
One trial in dental pain followed third molar extraction
[30], two were in pain the day after laparotomy [32,33],
and one the day after orthopaedic surgery [31]. Three of
the four trials were conducted following the discontinua-
tion of patient-controlled analgesia [31–33]. Including
active comparators there were 917 patients included
across the four trials; 221 were treated with parecoxib 20
mg, 223 with parecoxib 40 mg and 176 with placebo. All
four studies used intravenous (IV) parecoxib. One study
Table 1: Efficacy results
Number (%) of patients with at 
least 50% pain relief
Drug and dose Number of 
trials
Active Placebo Relative benefit 
(95% CI)
NNT (95% CI) Route
Valdecoxib 20 mg 2 69/101 (68) 8/103 (8) 8.8 (4.5 to 17.3) 1.7 (1.4 to 2.0) Oral
Valdecoxib 40 mg 4 204/279 (73) 19/194 (10) 7.3 (4.8 to 11.2) 1.6 (1.4 to 1.8) Oral
Parecoxib 20 mg 4 85/170 (50) 29/176 (16) 3.1 (2.2 to 4.5) 3.0 (2.3 to 4.1) Intravenous
Parecoxib 40 mg 4 109/173 (63) 29/176 (16) 3.8 (2.7 to 5.5) 2.2 (1.8 to 2.7) Intravenous
Parecoxib 20 mg 1 32/51 (63) 2/51 (4) 16 (4.1 to 63.3) 1.7 (1.4 to 2.3) Intramuscular
Parecoxib 40 mg 1 39/50 (78) 2/51 (4) 19.9 (5.1 to 78) 1.4 (1.2 to 1.6) Intramuscular
Table 2: Adverse effects
Number (%) of patients with adverse effects
Adverse effect Parecoxib 20 mg 
(IV)
Parecoxib 40 mg 
(IV)
Placebo Valdecoxib 40 mg 
(oral)
Placebo
Any effect 86/132 (65) 77/131 (59) 73/132 (55) 63/180 (35) 76/144 (53)
Headache 15/132 (11) 14/131 (11) 17/132 (13) 18/180 (10) 36/144 (25)
Nausea 32/132 (24) 25/131 (19) 31/132 (23) 21/180 (12) 30/144 (21)
Vomiting 16/132 (12) 13/131 (10) 11/132 (8) 15/180 (12) 15/144 (10)BMC Anesthesiology 2003, 3 http://www.biomedcentral.com/1471-2253/3/1
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[30] also reported the results of intramuscular (IM)
administration using the same doses. Comparator analge-
sics incorporated into study design were ketorolac IV or
IM (30 mg or 60 mg) in four studies and morphine (4 mg
IV) in three studies. Quality scores were 5 for one study, 4
for two studies and 3 for one study.
At least 50% pain relief
All four studies provided data that permitted the calcula-
tion of six hour TOTPAR and derivation of the number of
patients with at least 50%maxTOTPAR. Visual assessment
of homogeneity showed all the studies to be in good
agreement, all trials showed statistical benefit of
parecoxib 20 mg IV and 40 mg IV over placebo (Figure 2).
One trial [30] also showed statistical benefit of parecoxib
20 mg IM and 40 mg IM over placebo. Overall 85/170
patients (50%) given parecoxib 20 mg IV experienced at
least 50% maxTOTPAR over six hours compared with 29/
176 patients (16%) with placebo in direct comparison.
The NNT for one patient to have at least 50% pain relief
over six hours was 3.0 (2.3 to 4.1). For parecoxib 40 mg
IV, 109/173 patients (63%) experienced at least 50% max-
TOTPAR over six hours compared with 29/176 patients
(16%) with placebo in direct comparison. The NNT for
one patient to have at least half pain relief over six hours
was 2.3 (2.0 to 2.6). The NNTs for both doses given intra-
muscularly were lower (better) but patient numbers, at
about 100 in the comparison, were too small to exclude
the effects of chance (Table 1). Sensitivity analyses
between dental and postsurgical pain models showed sig-
nificant differences for both parecoxib 20 mg (z = 3.36, p
= 0.00067) and 40 mg (z = 3.15, p = 0.00137). Signifi-
cantly fewer patients with moderate to severe postsurgical
pain experienced 50% pain relief compared to patients
with moderate to severe dental pain.
L'Abbe plot showing trials of parecoxib 20 mg and 40 mg Figure 2
L'Abbe plot showing trials of parecoxib 20 mg and 40 mg.
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Remedication time
Trials discouraged remedication within the first 90 min-
utes but seven patients withdrew before completing the
first hour assessment [32,33]. The median time to remed-
ication was reported in all four studies. For placebo the
weighted median time to remedication from 125 patients
was 1.6 hours. For parecoxib 20 mg IV the weighted
median time to remedication based on 170 patients was
5.6 hours, for parecoxib 40 mg IV the weighted median
time to remedication from 173 patients was 8.7 hours.
The one report of parecoxib 40 mg in dental pain gave a
greater median time to remedication of 15.4 hours (11.1
hours to >24 hours) (addional file 1). The weighted mean
time to remedication for ketorolac 30 mg IV was 5.5 hours
(based on 121 patients) and for morphine 4 mg IV 3
hours (Figure 3).
Adverse effects
An adverse effect of some type was reported by 55% (73/
132) of patients on placebo, 65% (86/132) of patients on
parecoxib 20 mg IV and 55% (73/132) of patients on
parecoxib 40 mg IV. Three trial reports included the pro-
portion of patients experiencing different adverse events
(additional file 1). Pooled analyses of available data for
headache, nausea and vomiting revealed no significant
differences between either dose of parecoxib IV and pla-
cebo (Table 2). The absolute proportions of patients
experiencing adverse effects were highest with parecoxib
40 mg IV or placebo. There was no mention of adverse
reactions or irritation at injection site.
Discussion
The meta-analyses included in this review combined data
from randomised, double-blind trials that used the same
methods, the same outcomes, the same patients over the
Median time to remedication (weighted by number of patients) for valdecoxib, parecoxib and other analgesics. Figure 3
Median time to remedication (weighted by number of patients) for valdecoxib, parecoxib and other analgesics.
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same period of time to ensure quality and credibility
whilst minimising the threat of bias. Compared with pla-
cebo the NNT for at least 50% pain relief with a single
dose of valdecoxib 40 mg over six hours was 1.6 (1.4 to
1.8) and 1.7 (1.4 to 2.0) for valdecoxib 20 mg. There was
no significant difference in efficacy over 4 to 6 hours
between valdecoxib 20 mg and 40 mg, though the 40 mg
dose provided a longer duration of action (Figure 3). The
NNT for parecoxib 40 mg IV was 2.2 (1.8 to 2.7) and 3.0
(2.3 to 4.1) for parecoxib 20 mg IV. These differences in
efficacy were again not significant and the 40 mg IV dose
resulted in a slightly extended duration of action (Figure
3). The difference between pain models was based on one
dental trial compared with one laparotomy and two
orthopaedic trials, and while a statistically significant dif-
ference was obtained, little weight can be given to this
result without substantially more data. Adverse effects did
not occur any more frequently with valdecoxib or
parecoxib than with placebo however these results do not
necessarily extrapolate to other scenarios, particularly
chronic dosing [3,35].
The methods of this review are well-established and clini-
cal homogeneity assured by the inclusion criteria. It is
therefore legitimate to compare these results with reviews
of other oral and parenteral analgesics conducted in the
same way [38,39]. Both doses of valdecoxib had slightly
lower (better) NNTs than other oral comparators (Table
3). The extended duration of analgesia, afforded particu-
larly by valdecoxib 40 mg after third molar extraction,
would seem worthwhile and exceeds that of other oral
comparators (the weighted median time to remedication
for ibuprofen 400 mg is 7.4 hours [5], the weighted
median time to remedication for diclofenac 50 mg is 6.7
hours [38]). Parecoxib 20 mg IV had a lower (better) NNT
than ketorolac 30 mg IM, parecoxib 40 mg IV had a lower
(better) NNT than morphine 10 mg IM. Again, extended
duration of action would seem to be a potential benefit.
Parecoxib 20 mg IV was comparable with ketorolac 30 mg
IV but the duration of parecoxib 40 mg IV exceeded that
of ketorolac 30 mg, providing an additional three to four
hours pain relief (though the duration of analgesia with
ketorolac 60 mg IV was not available for further
comparison).
Longer duration of analgesia is an important benefit seen
here with oral valdecoxib 20 mg and 40 mg and injected
parecoxib 20 mg and 40 mg, and seen previously for oral
rofecoxib 50 mg (Figure 3). One reason for this longer
duration of action is that doses of coxibs used to achieve
this are between one and four times the usual daily dose
(usually 10 mg or 20 mg for valdecoxib, and 12.5 mg or
25 mg for rofecoxib). Compare this with, say, diclofenac,
where an acute pain dose might be 25 mg or 50 mg, some
one-sixth to one-third of the maximum daily dose of 150
mg. There should also be a note of caution. Clearly the
very long duration of action after third molar extraction –
up to 24 hours with valdecoxib 40 mg – is better than
older NSAIDs [5]. After other types of surgery the same
long duration was not achieved to the same extent.
Duration of analgesia may relate both to dose and specific
clinical circumstance.
Table 3: NNT League table showing valdecoxib and parecoxib alongside other analgesics
Oral analgesics
Drug and dose Number of patients in comparison NNT (95% CI)
Valdecoxib 40 mg 473 1.6 (1.4 to 1.8)
Valdecoxib 20 mg 204 1.7 (1.4 to 2.0)
Rofecoxib 50 mg1 675 2.3 (2.0 to 2.6)
Diclofenac 50 mg2 738 2.3 (2.0 to 2.7)
Ibuprofen 400 mg2 4703 2.4 (2.3 to 2.6)
Parenteral analgesics
Drug and dose Number of patients in comparison NNT (95% CI)
Parecoxib 40 mg IV 349 2.2 (1.8 to 2.7)
Morphine 10 mg IM3 946 2.9 (2.6 to 3.6)
Parecoxib 20 mg IV 346 3.0 (2.3 to 4.1)
Ketorolac 30 mg IM4 359 3.4 (2.5 to 4.9)
1. Barden et al. BMC Anesthesiol. 2002 Jun 9; 2(1):4. 2. In press update of Collins et al. Cochrane Database Syst Rev. 2000; (2):CD001548. 3. 
McQuay et al. JPSM. 1999 Mar; 17(3):164–174. 4. Smith et al. Brit J Anaesth. 2000; 84:48–58.BMC Anesthesiology 2003, 3 http://www.biomedcentral.com/1471-2253/3/1
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Perhaps the greatest advantage of meta-analysis is that by
combining appropriate data the threat of random chance
associated with small patient numbers is reduced. Meth-
odological research has demonstrated that data from
about 200 patients will be needed for credible estimates
when the NNT is 2 and about 1,000 patients when the
NNT is 3 to be 95% confident that the NNT is true ± 0.5
of the observed value [10,11](The numbers of trials (and
patients) included in the other analyses, though small
compared to other published systematic reviews [38,39],
is large enough to justify a certain degree of confidence in
the conclusions.
Conclusions
The comparisons between valdecoxib and parecoxib are
important and address potentially significant methodo-
logical issues for pain research around the coxibs. Val-
decoxib is a highly effective oral analgesic with an
extended duration of action in dental pain. Parecoxib is
also highly effective with a duration comparable with
older NSAIDs. The difference between the two drugs is in
target usage. Valdecoxib is more efficacious and has a
longer duration of action than other oral NSAIDs and cox-
ibs; parecoxib brings the benefits of an injectable coxib
drug to the peri-operative and immediate post-operative
period as well as to patients who are unable to swallow or
are nauseated and vomiting.
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